

Global Lung Disease Therapeutics Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/GFB20387AF54EN.html>

Date: March 2023

Pages: 110

Price: US\$ 4,480.00 (Single User License)

ID: GFB20387AF54EN

Abstracts

The global Lung Disease Therapeutics market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Lung Disease Therapeutics demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Lung Disease Therapeutics, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Lung Disease Therapeutics that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Lung Disease Therapeutics total market, 2018-2029, (USD Million)

Global Lung Disease Therapeutics total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Lung Disease Therapeutics total market, key domestic companies and share, (USD Million)

Global Lung Disease Therapeutics revenue by player and market share 2018-2023, (USD Million)

Global Lung Disease Therapeutics total market by Disease Type, CAGR, 2018-2029,

(USD Million)

Global Lung Disease Therapeutics total market by Distribution Channel, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Lung Disease Therapeutics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Mylan, Vertex Pharmaceuticals, F. Hoffman La Roche, Teva Pharmaceuticals and Cipla, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Lung Disease Therapeutics market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Disease Type, and by Distribution Channel. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Lung Disease Therapeutics Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Lung Disease Therapeutics Market, Segmentation by Disease Type

Asthma

Chronic Obstructive Pulmonary Disease (COPD)

Lung Cancer

Other Lung Diseases

Global Lung Disease Therapeutics Market, Segmentation by Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Companies Profiled:

GSK

AstraZeneca

Boehringer Ingelheim

Novartis

Mylan

Vertex Pharmaceuticals

F. Hoffman La Roche

Teva Pharmaceuticals

Cipla

Fibrogen

Liminal Biosciences

PharmAkea Therapeutics

IQVIA

Key Questions Answered

1. How big is the global Lung Disease Therapeutics market?
2. What is the demand of the global Lung Disease Therapeutics market?
3. What is the year over year growth of the global Lung Disease Therapeutics market?
4. What is the total value of the global Lung Disease Therapeutics market?
5. Who are the major players in the global Lung Disease Therapeutics market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Lung Disease Therapeutics Introduction
- 1.2 World Lung Disease Therapeutics Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Lung Disease Therapeutics Total Market by Region (by Headquarter Location)
 - 1.3.1 World Lung Disease Therapeutics Market Size by Region (2018-2029), (by Headquarter Location)
 - 1.3.2 United States Lung Disease Therapeutics Market Size (2018-2029)
 - 1.3.3 China Lung Disease Therapeutics Market Size (2018-2029)
 - 1.3.4 Europe Lung Disease Therapeutics Market Size (2018-2029)
 - 1.3.5 Japan Lung Disease Therapeutics Market Size (2018-2029)
 - 1.3.6 South Korea Lung Disease Therapeutics Market Size (2018-2029)
 - 1.3.7 ASEAN Lung Disease Therapeutics Market Size (2018-2029)
 - 1.3.8 India Lung Disease Therapeutics Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Lung Disease Therapeutics Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Lung Disease Therapeutics Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
 - 1.5.1 Influence of COVID-19
 - 1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

- 2.1 World Lung Disease Therapeutics Consumption Value (2018-2029)
- 2.2 World Lung Disease Therapeutics Consumption Value by Region
 - 2.2.1 World Lung Disease Therapeutics Consumption Value by Region (2018-2023)
 - 2.2.2 World Lung Disease Therapeutics Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Lung Disease Therapeutics Consumption Value (2018-2029)
- 2.4 China Lung Disease Therapeutics Consumption Value (2018-2029)
- 2.5 Europe Lung Disease Therapeutics Consumption Value (2018-2029)
- 2.6 Japan Lung Disease Therapeutics Consumption Value (2018-2029)
- 2.7 South Korea Lung Disease Therapeutics Consumption Value (2018-2029)
- 2.8 ASEAN Lung Disease Therapeutics Consumption Value (2018-2029)
- 2.9 India Lung Disease Therapeutics Consumption Value (2018-2029)

3 WORLD LUNG DISEASE THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Lung Disease Therapeutics Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)
 - 3.2.1 Global Lung Disease Therapeutics Industry Rank of Major Players
 - 3.2.2 Global Concentration Ratios (CR4) for Lung Disease Therapeutics in 2022
 - 3.2.3 Global Concentration Ratios (CR8) for Lung Disease Therapeutics in 2022
- 3.3 Lung Disease Therapeutics Company Evaluation Quadrant
- 3.4 Lung Disease Therapeutics Market: Overall Company Footprint Analysis
 - 3.4.1 Lung Disease Therapeutics Market: Region Footprint
 - 3.4.2 Lung Disease Therapeutics Market: Company Product Type Footprint
 - 3.4.3 Lung Disease Therapeutics Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: Lung Disease Therapeutics Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: Lung Disease Therapeutics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
 - 4.1.2 United States VS China: Lung Disease Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Lung Disease Therapeutics Consumption Value Comparison
 - 4.2.1 United States VS China: Lung Disease Therapeutics Consumption Value Comparison (2018 & 2022 & 2029)
 - 4.2.2 United States VS China: Lung Disease Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Lung Disease Therapeutics Companies and Market Share, 2018-2023
 - 4.3.1 United States Based Lung Disease Therapeutics Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Lung Disease Therapeutics Revenue, (2018-2023)

4.4 China Based Companies Lung Disease Therapeutics Revenue and Market Share, 2018-2023

4.4.1 China Based Lung Disease Therapeutics Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Lung Disease Therapeutics Revenue, (2018-2023)

4.5 Rest of World Based Lung Disease Therapeutics Companies and Market Share, 2018-2023

4.5.1 Rest of World Based Lung Disease Therapeutics Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies Lung Disease Therapeutics Revenue, (2018-2023)

5 MARKET ANALYSIS BY DISEASE TYPE

5.1 World Lung Disease Therapeutics Market Size Overview by Disease Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Disease Type

5.2.1 Asthma

5.2.2 Chronic Obstructive Pulmonary Disease (COPD)

5.2.3 Lung Cancer

5.2.4 Other Lung Diseases

5.3 Market Segment by Disease Type

5.3.1 World Lung Disease Therapeutics Market Size by Disease Type (2018-2023)

5.3.2 World Lung Disease Therapeutics Market Size by Disease Type (2024-2029)

5.3.3 World Lung Disease Therapeutics Market Size Market Share by Disease Type (2018-2029)

6 MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1 World Lung Disease Therapeutics Market Size Overview by Distribution Channel: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Distribution Channel

6.2.1 Hospital Pharmacies

6.2.2 Retail Pharmacies

6.2.3 Online Pharmacies

6.3 Market Segment by Distribution Channel

6.3.1 World Lung Disease Therapeutics Market Size by Distribution Channel

(2018-2023)

6.3.2 World Lung Disease Therapeutics Market Size by Distribution Channel

(2024-2029)

6.3.3 World Lung Disease Therapeutics Market Size by Distribution Channel

(2018-2029)

7 COMPANY PROFILES

7.1 GSK

7.1.1 GSK Details

7.1.2 GSK Major Business

7.1.3 GSK Lung Disease Therapeutics Product and Services

7.1.4 GSK Lung Disease Therapeutics Revenue, Gross Margin and Market Share

(2018-2023)

7.1.5 GSK Recent Developments/Updates

7.1.6 GSK Competitive Strengths & Weaknesses

7.2 AstraZeneca

7.2.1 AstraZeneca Details

7.2.2 AstraZeneca Major Business

7.2.3 AstraZeneca Lung Disease Therapeutics Product and Services

7.2.4 AstraZeneca Lung Disease Therapeutics Revenue, Gross Margin and Market

Share (2018-2023)

7.2.5 AstraZeneca Recent Developments/Updates

7.2.6 AstraZeneca Competitive Strengths & Weaknesses

7.3 Boehringer Ingelheim

7.3.1 Boehringer Ingelheim Details

7.3.2 Boehringer Ingelheim Major Business

7.3.3 Boehringer Ingelheim Lung Disease Therapeutics Product and Services

7.3.4 Boehringer Ingelheim Lung Disease Therapeutics Revenue, Gross Margin and

Market Share (2018-2023)

7.3.5 Boehringer Ingelheim Recent Developments/Updates

7.3.6 Boehringer Ingelheim Competitive Strengths & Weaknesses

7.4 Novartis

7.4.1 Novartis Details

7.4.2 Novartis Major Business

7.4.3 Novartis Lung Disease Therapeutics Product and Services

7.4.4 Novartis Lung Disease Therapeutics Revenue, Gross Margin and Market Share

(2018-2023)

7.4.5 Novartis Recent Developments/Updates

7.4.6 Novartis Competitive Strengths & Weaknesses

7.5 Mylan

7.5.1 Mylan Details

7.5.2 Mylan Major Business

7.5.3 Mylan Lung Disease Therapeutics Product and Services

7.5.4 Mylan Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.5.5 Mylan Recent Developments/Updates

7.5.6 Mylan Competitive Strengths & Weaknesses

7.6 Vertex Pharmaceuticals

7.6.1 Vertex Pharmaceuticals Details

7.6.2 Vertex Pharmaceuticals Major Business

7.6.3 Vertex Pharmaceuticals Lung Disease Therapeutics Product and Services

7.6.4 Vertex Pharmaceuticals Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.6.5 Vertex Pharmaceuticals Recent Developments/Updates

7.6.6 Vertex Pharmaceuticals Competitive Strengths & Weaknesses

7.7 F. Hoffman La Roche

7.7.1 F. Hoffman La Roche Details

7.7.2 F. Hoffman La Roche Major Business

7.7.3 F. Hoffman La Roche Lung Disease Therapeutics Product and Services

7.7.4 F. Hoffman La Roche Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.7.5 F. Hoffman La Roche Recent Developments/Updates

7.7.6 F. Hoffman La Roche Competitive Strengths & Weaknesses

7.8 Teva Pharmaceuticals

7.8.1 Teva Pharmaceuticals Details

7.8.2 Teva Pharmaceuticals Major Business

7.8.3 Teva Pharmaceuticals Lung Disease Therapeutics Product and Services

7.8.4 Teva Pharmaceuticals Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.8.5 Teva Pharmaceuticals Recent Developments/Updates

7.8.6 Teva Pharmaceuticals Competitive Strengths & Weaknesses

7.9 Cipla

7.9.1 Cipla Details

7.9.2 Cipla Major Business

7.9.3 Cipla Lung Disease Therapeutics Product and Services

7.9.4 Cipla Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

- 7.9.5 Cipla Recent Developments/Updates
- 7.9.6 Cipla Competitive Strengths & Weaknesses
- 7.10 Fibrogen
 - 7.10.1 Fibrogen Details
 - 7.10.2 Fibrogen Major Business
 - 7.10.3 Fibrogen Lung Disease Therapeutics Product and Services
 - 7.10.4 Fibrogen Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.10.5 Fibrogen Recent Developments/Updates
 - 7.10.6 Fibrogen Competitive Strengths & Weaknesses
- 7.11 Liminal Biosciences
 - 7.11.1 Liminal Biosciences Details
 - 7.11.2 Liminal Biosciences Major Business
 - 7.11.3 Liminal Biosciences Lung Disease Therapeutics Product and Services
 - 7.11.4 Liminal Biosciences Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.11.5 Liminal Biosciences Recent Developments/Updates
 - 7.11.6 Liminal Biosciences Competitive Strengths & Weaknesses
- 7.12 PharmAkea Therapeutics
 - 7.12.1 PharmAkea Therapeutics Details
 - 7.12.2 PharmAkea Therapeutics Major Business
 - 7.12.3 PharmAkea Therapeutics Lung Disease Therapeutics Product and Services
 - 7.12.4 PharmAkea Therapeutics Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.12.5 PharmAkea Therapeutics Recent Developments/Updates
 - 7.12.6 PharmAkea Therapeutics Competitive Strengths & Weaknesses
- 7.13 IQVIA
 - 7.13.1 IQVIA Details
 - 7.13.2 IQVIA Major Business
 - 7.13.3 IQVIA Lung Disease Therapeutics Product and Services
 - 7.13.4 IQVIA Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.13.5 IQVIA Recent Developments/Updates
 - 7.13.6 IQVIA Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 Lung Disease Therapeutics Industry Chain
- 8.2 Lung Disease Therapeutics Upstream Analysis

8.3 Lung Disease Therapeutics Midstream Analysis

8.4 Lung Disease Therapeutics Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. World Lung Disease Therapeutics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
- Table 2. World Lung Disease Therapeutics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
- Table 3. World Lung Disease Therapeutics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
- Table 4. World Lung Disease Therapeutics Revenue Market Share by Region (2018-2023), (by Headquarter Location)
- Table 5. World Lung Disease Therapeutics Revenue Market Share by Region (2024-2029), (by Headquarter Location)
- Table 6. Major Market Trends
- Table 7. World Lung Disease Therapeutics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
- Table 8. World Lung Disease Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
- Table 9. World Lung Disease Therapeutics Consumption Value Forecast by Region (2024-2029) & (USD Million)
- Table 10. World Lung Disease Therapeutics Revenue by Player (2018-2023) & (USD Million)
- Table 11. Revenue Market Share of Key Lung Disease Therapeutics Players in 2022
- Table 12. World Lung Disease Therapeutics Industry Rank of Major Player, Based on Revenue in 2022
- Table 13. Global Lung Disease Therapeutics Company Evaluation Quadrant
- Table 14. Head Office of Key Lung Disease Therapeutics Player
- Table 15. Lung Disease Therapeutics Market: Company Product Type Footprint
- Table 16. Lung Disease Therapeutics Market: Company Product Application Footprint
- Table 17. Lung Disease Therapeutics Mergers & Acquisitions Activity
- Table 18. United States VS China Lung Disease Therapeutics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
- Table 19. United States VS China Lung Disease Therapeutics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
- Table 20. United States Based Lung Disease Therapeutics Companies, Headquarters (States, Country)
- Table 21. United States Based Companies Lung Disease Therapeutics Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Lung Disease Therapeutics Revenue Market Share (2018-2023)

Table 23. China Based Lung Disease Therapeutics Companies, Headquarters (Province, Country)

Table 24. China Based Companies Lung Disease Therapeutics Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Lung Disease Therapeutics Revenue Market Share (2018-2023)

Table 26. Rest of World Based Lung Disease Therapeutics Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Lung Disease Therapeutics Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Lung Disease Therapeutics Revenue Market Share (2018-2023)

Table 29. World Lung Disease Therapeutics Market Size by Disease Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Lung Disease Therapeutics Market Size by Disease Type (2018-2023) & (USD Million)

Table 31. World Lung Disease Therapeutics Market Size by Disease Type (2024-2029) & (USD Million)

Table 32. World Lung Disease Therapeutics Market Size by Distribution Channel, (USD Million), 2018 & 2022 & 2029

Table 33. World Lung Disease Therapeutics Market Size by Distribution Channel (2018-2023) & (USD Million)

Table 34. World Lung Disease Therapeutics Market Size by Distribution Channel (2024-2029) & (USD Million)

Table 35. GSK Basic Information, Area Served and Competitors

Table 36. GSK Major Business

Table 37. GSK Lung Disease Therapeutics Product and Services

Table 38. GSK Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. GSK Recent Developments/Updates

Table 40. GSK Competitive Strengths & Weaknesses

Table 41. AstraZeneca Basic Information, Area Served and Competitors

Table 42. AstraZeneca Major Business

Table 43. AstraZeneca Lung Disease Therapeutics Product and Services

Table 44. AstraZeneca Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 45. AstraZeneca Recent Developments/Updates

Table 46. AstraZeneca Competitive Strengths & Weaknesses
Table 47. Boehringer Ingelheim Basic Information, Area Served and Competitors
Table 48. Boehringer Ingelheim Major Business
Table 49. Boehringer Ingelheim Lung Disease Therapeutics Product and Services
Table 50. Boehringer Ingelheim Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Boehringer Ingelheim Recent Developments/Updates
Table 52. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 53. Novartis Basic Information, Area Served and Competitors
Table 54. Novartis Major Business
Table 55. Novartis Lung Disease Therapeutics Product and Services
Table 56. Novartis Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Novartis Recent Developments/Updates
Table 58. Novartis Competitive Strengths & Weaknesses
Table 59. Mylan Basic Information, Area Served and Competitors
Table 60. Mylan Major Business
Table 61. Mylan Lung Disease Therapeutics Product and Services
Table 62. Mylan Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Mylan Recent Developments/Updates
Table 64. Mylan Competitive Strengths & Weaknesses
Table 65. Vertex Pharmaceuticals Basic Information, Area Served and Competitors
Table 66. Vertex Pharmaceuticals Major Business
Table 67. Vertex Pharmaceuticals Lung Disease Therapeutics Product and Services
Table 68. Vertex Pharmaceuticals Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Vertex Pharmaceuticals Recent Developments/Updates
Table 70. Vertex Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. F. Hoffman La Roche Basic Information, Area Served and Competitors
Table 72. F. Hoffman La Roche Major Business
Table 73. F. Hoffman La Roche Lung Disease Therapeutics Product and Services
Table 74. F. Hoffman La Roche Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. F. Hoffman La Roche Recent Developments/Updates
Table 76. F. Hoffman La Roche Competitive Strengths & Weaknesses
Table 77. Teva Pharmaceuticals Basic Information, Area Served and Competitors
Table 78. Teva Pharmaceuticals Major Business
Table 79. Teva Pharmaceuticals Lung Disease Therapeutics Product and Services

Table 80. Teva Pharmaceuticals Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 81. Teva Pharmaceuticals Recent Developments/Updates

Table 82. Teva Pharmaceuticals Competitive Strengths & Weaknesses

Table 83. Cipla Basic Information, Area Served and Competitors

Table 84. Cipla Major Business

Table 85. Cipla Lung Disease Therapeutics Product and Services

Table 86. Cipla Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 87. Cipla Recent Developments/Updates

Table 88. Cipla Competitive Strengths & Weaknesses

Table 89. Fibrogen Basic Information, Area Served and Competitors

Table 90. Fibrogen Major Business

Table 91. Fibrogen Lung Disease Therapeutics Product and Services

Table 92. Fibrogen Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 93. Fibrogen Recent Developments/Updates

Table 94. Fibrogen Competitive Strengths & Weaknesses

Table 95. Liminal Biosciences Basic Information, Area Served and Competitors

Table 96. Liminal Biosciences Major Business

Table 97. Liminal Biosciences Lung Disease Therapeutics Product and Services

Table 98. Liminal Biosciences Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 99. Liminal Biosciences Recent Developments/Updates

Table 100. Liminal Biosciences Competitive Strengths & Weaknesses

Table 101. PharmAkea Therapeutics Basic Information, Area Served and Competitors

Table 102. PharmAkea Therapeutics Major Business

Table 103. PharmAkea Therapeutics Lung Disease Therapeutics Product and Services

Table 104. PharmAkea Therapeutics Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 105. PharmAkea Therapeutics Recent Developments/Updates

Table 106. IQVIA Basic Information, Area Served and Competitors

Table 107. IQVIA Major Business

Table 108. IQVIA Lung Disease Therapeutics Product and Services

Table 109. IQVIA Lung Disease Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 110. Global Key Players of Lung Disease Therapeutics Upstream (Raw Materials)

Table 111. Lung Disease Therapeutics Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Lung Disease Therapeutics Picture

Figure 2. World Lung Disease Therapeutics Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Lung Disease Therapeutics Total Market Size (2018-2029) & (USD Million)

Figure 4. World Lung Disease Therapeutics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)

Figure 5. World Lung Disease Therapeutics Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Lung Disease Therapeutics Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Lung Disease Therapeutics Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Lung Disease Therapeutics Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Lung Disease Therapeutics Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Lung Disease Therapeutics Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Lung Disease Therapeutics Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Lung Disease Therapeutics Revenue (2018-2029) & (USD Million)

Figure 13. Lung Disease Therapeutics Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Lung Disease Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 16. World Lung Disease Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Lung Disease Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 18. China Lung Disease Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Lung Disease Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Lung Disease Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Lung Disease Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Lung Disease Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 23. India Lung Disease Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Lung Disease Therapeutics by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Lung Disease Therapeutics Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Lung Disease Therapeutics Markets in 2022

Figure 27. United States VS China: Lung Disease Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Lung Disease Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Lung Disease Therapeutics Market Size by Disease Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Lung Disease Therapeutics Market Size Market Share by Disease Type in 2022

Figure 31. Asthma

Figure 32. Chronic Obstructive Pulmonary Disease (COPD)

Figure 33. Lung Cancer

Figure 34. Other Lung Diseases

Figure 35. World Lung Disease Therapeutics Market Size Market Share by Disease Type (2018-2029)

Figure 36. World Lung Disease Therapeutics Market Size by Distribution Channel, (USD Million), 2018 & 2022 & 2029

Figure 37. World Lung Disease Therapeutics Market Size Market Share by Distribution Channel in 2022

Figure 38. Hospital Pharmacies

Figure 39. Retail Pharmacies

Figure 40. Online Pharmacies

Figure 41. Lung Disease Therapeutics Industrial Chain

Figure 42. Methodology

Figure 43. Research Process and Data Source

I would like to order

Product name: Global Lung Disease Therapeutics Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/GFB20387AF54EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFB20387AF54EN.html>